Leukemia & Lymphoma ›

Volume 56, 2015 - Issue 4

258 Views | 3 CrossRef citations to date | 0 Altmetric

Original Article: Clinical

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

Eric Jacobsen, Olga Pozdnyakova, Robert Redd, David C. Fisher, David M. Dorfman, Paola Dal Cin, ...show all

Pages 993-998 | Received 03 Jun 2014, Accepted 30 Jun 2014, Accepted author version posted online: 11 Jul 2014, Published online: 20 Aug 2014

Cite this article https://doi.org/10.3109/10428194.2014.941835 Check for updates

Sample our Medicine, Dentistry, Nursing & Allied Health Journals
>> Sign in here to start your access to the latest two volumes for 14 days

Full Article Figures & data References Supplemental Citations Metrics

Reprints & Permissions Read this article Share

Abstract

Platelet derived growth factor-α (PDGFR-α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR-α expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1–PDGFR-α fusion and/or PDGFR-α amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis

of PDGFR-α by immunohistochemistry and three of these patients' tumors expressed PDGFR-α. Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR-α expression was not required for study entry.

Keywords::

Lymphoma imatinib PDGFR-α

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.



Related research

People also read | Recommended articles | Cited by 3

Information for

Authors
R&D professionals
Editors
Librarians
Societies

Open access

Overview
Open journals
Open Select
Dove Medical Press
F1000Research

Opportunities

Reprints and e-prints
Advertising solutions
Accelerated publication
Corporate access solutions

Help and information

Help and contact
Newsroom
All journals
Books

Keep up to date

Register to receive personalised research and resources by email

Sign me up

Copyright © 2026 Informa UK Limited Privacy policy

Cookies Terms & conditions Accessibility

Registered in England & Wales No. 01072954
5 Howick Place | London | SW1P 1WG